JP2019535287A - Crispr/cpf1システム及び方法 - Google Patents
Crispr/cpf1システム及び方法 Download PDFInfo
- Publication number
- JP2019535287A JP2019535287A JP2019527441A JP2019527441A JP2019535287A JP 2019535287 A JP2019535287 A JP 2019535287A JP 2019527441 A JP2019527441 A JP 2019527441A JP 2019527441 A JP2019527441 A JP 2019527441A JP 2019535287 A JP2019535287 A JP 2019535287A
- Authority
- JP
- Japan
- Prior art keywords
- crrna
- cpf1
- seq
- ascpf1
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 34
- 108091033409 CRISPR Proteins 0.000 title abstract description 30
- 238000010354 CRISPR gene editing Methods 0.000 title abstract 2
- 101150005393 CBF1 gene Proteins 0.000 title description 3
- 101100329224 Coprinopsis cinerea (strain Okayama-7 / 130 / ATCC MYA-4618 / FGSC 9003) cpf1 gene Proteins 0.000 title description 3
- 101150059443 cas12a gene Proteins 0.000 title description 3
- 101000860090 Acidaminococcus sp. (strain BV3L6) CRISPR-associated endonuclease Cas12a Proteins 0.000 claims abstract description 176
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 86
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 74
- 229920001184 polypeptide Polymers 0.000 claims abstract description 73
- 108010042407 Endonucleases Proteins 0.000 claims abstract description 53
- 102000004533 Endonucleases Human genes 0.000 claims abstract description 53
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 44
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 43
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 43
- 238000010362 genome editing Methods 0.000 claims abstract description 39
- 238000007385 chemical modification Methods 0.000 claims abstract description 29
- 102000004389 Ribonucleoproteins Human genes 0.000 claims abstract description 24
- 108010081734 Ribonucleoproteins Proteins 0.000 claims abstract description 24
- 210000004027 cell Anatomy 0.000 claims description 134
- 108090000623 proteins and genes Proteins 0.000 claims description 69
- 102000004169 proteins and genes Human genes 0.000 claims description 61
- 230000004048 modification Effects 0.000 claims description 59
- 238000012986 modification Methods 0.000 claims description 59
- 230000014509 gene expression Effects 0.000 claims description 35
- 239000013604 expression vector Substances 0.000 claims description 20
- 210000005260 human cell Anatomy 0.000 claims description 14
- 125000003729 nucleotide group Chemical group 0.000 claims description 14
- 238000004904 shortening Methods 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 12
- 108020004705 Codon Proteins 0.000 claims description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 125000006850 spacer group Chemical group 0.000 claims description 7
- 241000282412 Homo Species 0.000 claims description 6
- 241000282414 Homo sapiens Species 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 abstract description 19
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 73
- 235000018102 proteins Nutrition 0.000 description 58
- 108020004414 DNA Proteins 0.000 description 51
- 230000000694 effects Effects 0.000 description 43
- 238000003776 cleavage reaction Methods 0.000 description 37
- 230000007017 scission Effects 0.000 description 37
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 35
- 208000009869 Neu-Laxova syndrome Diseases 0.000 description 30
- 108020005004 Guide RNA Proteins 0.000 description 24
- 101710163270 Nuclease Proteins 0.000 description 21
- 230000006870 function Effects 0.000 description 19
- 241000588724 Escherichia coli Species 0.000 description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 230000027455 binding Effects 0.000 description 16
- 238000001890 transfection Methods 0.000 description 16
- 238000004520 electroporation Methods 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 102000037865 fusion proteins Human genes 0.000 description 14
- 108020001507 fusion proteins Proteins 0.000 description 14
- 230000008685 targeting Effects 0.000 description 14
- 241000894007 species Species 0.000 description 13
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 12
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 11
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 238000000746 purification Methods 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 108091027305 Heteroduplex Proteins 0.000 description 8
- 101100231743 Homo sapiens HPRT1 gene Proteins 0.000 description 8
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 7
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 7
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 7
- 101710180995 Endonuclease 1 Proteins 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 108010090804 Streptavidin Proteins 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000003607 modifier Substances 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 6
- 108060002716 Exonuclease Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 102000013165 exonuclease Human genes 0.000 description 6
- 238000005457 optimization Methods 0.000 description 6
- 239000012098 Lipofectamine RNAiMAX Substances 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 101000896557 Homo sapiens Eukaryotic translation initiation factor 3 subunit B Proteins 0.000 description 4
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 4
- 101800005109 Triakontatetraneuropeptide Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000006780 non-homologous end joining Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- NMEHNETUFHBYEG-IHKSMFQHSA-N tttn Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 NMEHNETUFHBYEG-IHKSMFQHSA-N 0.000 description 4
- 208000035657 Abasia Diseases 0.000 description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 230000007018 DNA scission Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101000860092 Francisella tularensis subsp. novicida (strain U112) CRISPR-associated endonuclease Cas12a Proteins 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 108091081548 Palindromic sequence Proteins 0.000 description 3
- 239000000074 antisense oligonucleotide Substances 0.000 description 3
- 238000012230 antisense oligonucleotides Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 125000001921 locked nucleotide group Chemical group 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 3
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241001588186 Acidaminococcus sp. BV3L6 Species 0.000 description 2
- 241000203069 Archaea Species 0.000 description 2
- 101710201279 Biotin carboxyl carrier protein Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000945735 Homo sapiens Parafibromin Proteins 0.000 description 2
- 241001112693 Lachnospiraceae Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 102000002488 Nucleoplasmin Human genes 0.000 description 2
- 108700001094 Plant Genes Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 230000026279 RNA modification Effects 0.000 description 2
- 230000004570 RNA-binding Effects 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000011990 functional testing Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000011544 gradient gel Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000504 luminescence detection Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108060005597 nucleoplasmin Proteins 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 108010004901 Haloalkane dehalogenase Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 102100034743 Parafibromin Human genes 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 101150039863 Rich gene Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/30—Endoribonucleases active with either ribo- or deoxyribonucleic acids and producing 5'-phosphomonoesters (3.1.30)
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
本出願は、米国特許法119条の下、2016年11月22日に出願され、「CPF1 CRISPR SYSTEMS AND METHODS」と題する米国仮特許出願第62/425,307号、及び2017年4月7日に出願され、「HEK293 CELL LINE WITH STABLE EXPRESSION OF ACIDAMINOCOCCUS SP.BV3L6 CPF1」と題する米国仮特許出願第62/482,896号の優先権の利益を主張し、これらの内容は参照によりそれらの全体が本明細書に組み込まれる。
本出願は、EFS−Webを介してASCIIフォーマットにおいて提出された配列表を含み、参照によりその全体が本明細書に組み込まれる。___に作成されたASCIIコピーは、IDT01−010−US_ST25.txtという名称であり、___バイトサイズである。
本発明は、Cpf1ベースのCRISPR遺伝子、これによってコードされるポリペプチド、Cpf1を安定に発現する哺乳動物細胞株、crRNA並びにCRISPR−Cpf1システム及び方法の組成物におけるこれらの物質の使用に関する。
本発明は、Cpf1ベースのCRISPR遺伝子、これによってコードされるポリペプチド、Cpf1を安定に発現する哺乳動物細胞株、及び化学的に合成されたCpf1 crRNA、並びにCRISPR−Cpf1システム及び方法の組成物におけるこれらの使用に関する。例は、アシダミノコッカス属種BV3L6及びラクノスピラ科細菌ND2006由来のCpf1システムを利用することを示すが、これは他の種から単離されたCpf1ホモログ又はオルソログに及ぶ範囲を制限することを意図しない。
「野生型AsCpf1タンパク質」(「WT−AsCpf1」又は「WT−AsCpf1タンパク質」)という用語は、天然に存在するアシダミノコッカス属種BV3L6 Cpf1(例えば、配列番号2)の同一のアミノ酸配列を有し、活性CRISPR/Cpf1エンドヌクレアーゼシステムを形成するために適切なcrRNAと組み合わせた場合に生化学的及び生物学的活性を有するタンパク質を包含する。
「長さが修飾された」という用語は、この用語がRNAを修飾する場合、ヌクレオチド配列を欠いている参照RNAの短縮された若しくは切断された形態又はさらなるヌクレオチド配列を含む参照RNAの伸長された形態を指す。
単離された核酸ベクターにおいてコードされる野生型As Cpf1ポリペプチドのDNA及びアミノ酸配列
以下のリストは、本発明に記載されているポリペプチド融合タンパク質として発現される野生型(WT)As Cpf1ヌクレアーゼを示す。多くの場合、1つより多いコドンが同じアミノ酸をコードし得るので、多くの異なるDNA配列が同じアミノ酸(AA)配列をコードし得る/発現し得ることが、当業者によって理解される。以下に示されているDNA配列は例としてのみ与えられ、同じタンパク質(例えば、同じアミノ酸配列)をコードする他のDNA配列が意図される。NLSドメインなどのようなさらなる特徴、エレメント又はタグが、前記配列に付加されてもよいことがさらに理解される。Cpf1単独並びにC末端及びN末端の両方のSV40NLSドメイン及びHISタグと融合したCpf1としてこれらのタンパク質についてのアミノ酸及びDNA配列を示す、WT AsCpf1についての例を示す。NLS配列、ドメインリンカー又は精製タグを表すアミノ酸配列は太字のフォントで示される。
ヒトコドン最適化AsCpf1ポリペプチド融合タンパク質をコードする核酸を発現する単離されたベクター及びAs Cpf1ポリペプチド融合タンパク質を安定に発現するヒト細胞株の調製。
crRNAの長さ最適化:5’−20塩基ユニバーサルループドメインの切断の試験。
crRNAの長さ最適化:3’−24塩基標的特異的プロトスペーサードメインの切断の試験。
単一塩基の2’OMe修飾による、2つのAsCpf1 crRNAのウォークスルー(walk through)。
AsCpf1 crRNAにおける配列のブロックの修飾。
RNP複合体として送達されるAsCpf1タンパク質を伴う修飾crRNAの使用。
E.コリにおけるAsCpf1発現プラスミドによる修飾crRNAの使用
ヒトHPRT1遺伝子(38346)における部位をE.コリプラスミドにクローニングし、E.コリ細胞における部位特異的切断を実施するために化学的に修飾されたcrRNAを使用する能力を研究するために使用した。AsCpf1をプラスミドから発現させた。エレクトロポレーションを使用して、AsCpf1発現プラスミド及び化学合成したcrRNAの両方を送達した。
単離された核酸ベクターにおいてコードされる野生型Lb Cpf1ポリペプチドのDNA及びアミノ酸配列
以下のリストは、本発明に記載されているポリペプチド融合タンパク質として発現される野生型(WT)Lb Cpf1ヌクレアーゼを示す。多くの場合、1つより多いコドンが同じアミノ酸をコードし得るので、多くの異なるDNA配列は、同じアミノ酸(AA)配列をコードし得る/発現し得ることが、当業者によって理解される。以下に示されるDNA配列は例としてのみ役立ち、同じタンパク質(例えば、同じアミノ酸配列)をコードする他のDNA配列が意図される。NLSドメインなどのような、さらなる特徴、エレメント又はタグが、前記配列に付加されてもよいことは、さらに理解される。
RNP複合体として送達されるLbCpf1タンパク質を伴う修飾crRNAの使用。
本明細書に記載されている細胞株(例えば、1A1、2A2及び2B1)は、10801 University Blvd、Manassas、VA20110に位置し、_____に以下の受託番号:_____を割り当てられたアメリカンタイプカルチャーコレクション(ATCC)に寄託されている。
Claims (46)
- ヒト(H.sapiens)における発現のためにコドン最適化されたAs Cpf1ポリペプチドをコードする単離された核酸。
- 配列番号15を含む、請求項1に記載の単離された核酸。
- 野生型As Cpf1タンパク質をコードする単離されたポリペプチド。
- 配列番号12を含む、請求項3に記載の単離されたポリペプチド。
- 配列番号15をコードする単離された発現ベクター。
- 配列番号15をコードする単離された発現ベクターを含む宿主細胞であって、配列番号15をコードする単離された発現ベクターは、配列番号12を含むポリペプチドの発現を可能にするように適切なプロモーターに作動可能に連結している、宿主細胞。
- ヒト細胞を含む、請求項6に記載の宿主細胞。
- ヒト細胞が不死化細胞株を含む、請求項7に記載の宿主細胞。
- 不死化細胞株がHEK293細胞株である、請求項8に記載の宿主細胞。
- 野生型CRISPR/Cpf1エンドヌクレアーゼを形成するために、配列番号2、配列番号12、配列番号16及び配列番号19からなる群から選択されるポリペプチドと、リボ核タンパク質複合体を形成することができる単離されたAsCpf1 crRNAをさらに含む、請求項6に記載の宿主細胞株。
- AsCpf1ポリペプチド、及び
適切なAsCpf1 crRNA
を含む、単離されたCRISPR/Cpf1エンドヌクレアーゼシステム。 - AsCpf1ポリペプチドが配列番号12を含む、請求項11に記載の単離されたCRISPR/Cpf1エンドヌクレアーゼシステム。
- 適切なAsCpf1 crRNAが、長さが短縮されたAsCpf1 crRNA、又は化学的に修飾されたAsCpf1 crRNA、又は長さ短縮及び化学修飾の両方を含むAsCpf1 crRNAから選択される、請求項11に記載の単離されたCRISPR/Cpf1エンドヌクレアーゼシステム。
- AsCpf1ポリペプチド及び適切なAsCpf1 crRNAを発現するヒト細胞株を含む、単離されたCRISPR/Cpf1エンドヌクレアーゼシステム。
- AsCpf1ポリペプチドが配列番号12を含む、請求項14に記載の単離されたCRISPR/Cpf1エンドヌクレアーゼシステム。
- 適切なAsCpf1 crRNAが、長さが短縮されたAsCpf1 crRNA、又は化学的に修飾されたAsCpf1 crRNA、又は長さ短縮及び化学修飾の両方を含むAsCpf1 crRNAから選択される、請求項14に記載の単離されたCRISPR/Cpf1エンドヌクレアーゼシステム。
- 規則的な間隔をもってクラスター化された短鎖反復回文配列(CRISPR)/CRISPR関連タンパク質エンドヌクレアーゼシステムにおいて活性である、単離されたAsCpf1 crRNA。
- 長さが短縮されたAsCpf1 crRNA、化学的に修飾されたAsCpf1 crRNA、又は長さ短縮及び化学修飾の両方を含むAsCpf1 crRNAから選択される、請求項17に記載の単離されたAsCpf1 crRNA。
- 19〜20ヌクレオチド長の5’−ユニバーサルループドメイン及び19〜21ヌクレオチド長の3’標的特異的プロトスペーサードメインを含む長さが短縮されたAsCpf1 crRNAである、請求項17に記載の単離されたAsCpf1 crRNA。
- 長さ短縮及び化学修飾の両方を含む、請求項17に記載の単離されたAsCpf1 crRNA。
- 化学修飾が、末端基修飾(例えば、C3スペーサー)、2’OMe修飾、2’−フルオロ修飾、及びLNA修飾からなる群から選択される、請求項20に記載の単離されたAsCpf1 crRNA。
- 候補編集標的部位遺伝子座を、野生型AsCpf1ポリペプチド及び適切なAsCpf1 crRNAを有する活性CRISPR/Cpf1エンドヌクレアーゼシステムと接触させるステップを含む、遺伝子編集を実施する方法。
- 野生型AsCpf1ポリペプチドが、配列番号2、配列番号12、配列番号16及び配列番号19からなる群から選択される、請求項22に記載の方法。
- 適切なAsCpf1 crRNAが、長さが短縮されたAsCpf1 crRNA、化学的に修飾されたAsCpf1 crRNA、又は長さ短縮及び化学修飾の両方を含むAsCpf1 crRNAから選択される、請求項22に記載の方法。
- ヒトにおける発現のためにコドン最適化されたLb Cpf1ポリペプチドをコードする、単離された核酸。
- 配列番号17又は配列番号396を含む、請求項25に記載の単離された核酸。
- 野生型Lp Cpf1タンパク質をコードする、単離されたポリペプチド。
- 配列番号14又は配列番号24を含む、請求項27に記載の単離されたポリペプチド。
- 配列番号17又は配列番号396をコードする、単離された発現ベクター。
- 配列番号17又は配列番号396をコードする単離された発現ベクターを含む宿主細胞であって、配列番号17又は配列番号396をコードする単離された発現ベクターが、それぞれ配列番号14又は配列番号24を含むポリペプチドの発現を可能にするように適切なプロモーターに作動可能に連結している、宿主細胞。
- ヒト細胞を含む、請求項30に記載の宿主細胞。
- ヒト細胞が不死化細胞株を含む、請求項31に記載の宿主細胞。
- 不死化細胞株がHEK293細胞株である、請求項32に記載の宿主細胞。
- 野生型CRISPR/Cpf1エンドヌクレアーゼを形成するために、配列番号4、配列番号14、配列番号20及び配列番号24からなる群から選択されるポリペプチドと、リボ核タンパク質複合体を形成することができる単離されたLb Cpf1 crRNAをさらに含む、請求項30に記載の宿主細胞株。
- Lb Cpf1ポリペプチド及び
適切なCpf1 crRNA
を含む、単離されたCRISPR/Cpf1エンドヌクレアーゼシステム。 - Lb Cpf1ポリペプチドが配列番号14を含む、請求項35に記載の単離されたCRISPR/Cpf1エンドヌクレアーゼシステム。
- 適切なCpf1 crRNAが、長さが短縮されたCpf1 crRNA、又は化学的に修飾されたCpf1 crRNA、又は長さ短縮及び化学修飾の両方を含むCpf1 crRNAから選択される、請求項35に記載の単離されたCRISPR/Cpf1エンドヌクレアーゼシステム。
- Lb Cpf1ポリペプチド及び適切なCpf1 crRNAを発現するヒト細胞株を含む、単離されたCRISPR/Cpf1エンドヌクレアーゼシステム。
- Lb Cpf1ポリペプチドが、配列番号14又は配列番号24を含む、請求項38に記載の単離されたCRISPR/Cpf1エンドヌクレアーゼシステム。
- 適切なCpf1 crRNAが、長さが短縮されたCpf1 crRNA、又は化学的に修飾されたCpf1 crRNA、又は長さ短縮及び化学修飾の両方を含むCpf1 crRNAから選択される、請求項38に記載の単離されたCRISPR/Cpf1エンドヌクレアーゼシステム。
- 候補編集標的部位遺伝子座を、野生型Lb Cpf1ポリペプチド及び適切なCpf1 crRNAを有する活性CRISPR/Cpf1エンドヌクレアーゼシステムと接触させるステップを含む、遺伝子編集を実施する方法。
- 野生型Lb Cpf1ポリペプチドが、配列番号4、配列番号14、配列番号20及び配列番号24からなる群から選択される、請求項41に記載の方法。
- 適切なCpf1 crRNAが、長さが短縮されたCpf1 crRNA、化学的に修飾されたCpf1 crRNA、又は長さ短縮及び化学修飾の両方を含むCpf1 crRNAから選択される、請求項41に記載の方法。
- 適切なCpf1 crRNAが、19〜20ヌクレオチド長の5’−ユニバーサルループドメイン、及び19〜21ヌクレオチド長の3’標的特異的プロトスペーサードメインを含む、長さが短縮されたCpf1 crRNAである、請求項41に記載の方法。
- 適切なCpf1 crRNAが、長さ短縮及び化学修飾の両方を含む、請求項41に記載の方法。
- 化学修飾が、末端基修飾(例えば、C3スペーサー)、2’OMe修飾、2’−フルオロ修飾、及びLNA修飾からなる群から選択される、請求項45に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022193427A JP2023022254A (ja) | 2016-11-22 | 2022-12-02 | Crispr/cpf1システム及び方法 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662425307P | 2016-11-22 | 2016-11-22 | |
US62/425,307 | 2016-11-22 | ||
US201762482896P | 2017-04-07 | 2017-04-07 | |
US62/482,896 | 2017-04-07 | ||
PCT/US2017/063161 WO2018098383A1 (en) | 2016-11-22 | 2017-11-22 | Crispr/cpf1 systems and methods |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022193427A Division JP2023022254A (ja) | 2016-11-22 | 2022-12-02 | Crispr/cpf1システム及び方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2019535287A true JP2019535287A (ja) | 2019-12-12 |
Family
ID=62195662
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019527441A Pending JP2019535287A (ja) | 2016-11-22 | 2017-11-22 | Crispr/cpf1システム及び方法 |
JP2022193427A Pending JP2023022254A (ja) | 2016-11-22 | 2022-12-02 | Crispr/cpf1システム及び方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022193427A Pending JP2023022254A (ja) | 2016-11-22 | 2022-12-02 | Crispr/cpf1システム及び方法 |
Country Status (8)
Country | Link |
---|---|
US (2) | US11136567B2 (ja) |
EP (2) | EP4321617A3 (ja) |
JP (2) | JP2019535287A (ja) |
KR (1) | KR20190082318A (ja) |
CN (1) | CN110402287A (ja) |
AU (1) | AU2017364084A1 (ja) |
CA (1) | CA3044101A1 (ja) |
WO (1) | WO2018098383A1 (ja) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2853829C (en) | 2011-07-22 | 2023-09-26 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
US20150166982A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting pi3k point mutations |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
WO2016073990A2 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
CA2986310A1 (en) | 2015-05-11 | 2016-11-17 | Editas Medicine, Inc. | Optimized crispr/cas9 systems and methods for gene editing in stem cells |
JP7396783B2 (ja) | 2015-06-09 | 2023-12-12 | エディタス・メディシン、インコーポレイテッド | 移植を改善するためのcrispr/cas関連方法および組成物 |
WO2017004261A1 (en) | 2015-06-29 | 2017-01-05 | Ionis Pharmaceuticals, Inc. | Modified crispr rna and modified single crispr rna and uses thereof |
CA2999500A1 (en) | 2015-09-24 | 2017-03-30 | Editas Medicine, Inc. | Use of exonucleases to improve crispr/cas-mediated genome editing |
EP4269577A3 (en) | 2015-10-23 | 2024-01-17 | President and Fellows of Harvard College | Nucleobase editors and uses thereof |
WO2017165826A1 (en) | 2016-03-25 | 2017-09-28 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
EP4047092A1 (en) | 2016-04-13 | 2022-08-24 | Editas Medicine, Inc. | Cas9 fusion molecules, gene editing systems, and methods of use thereof |
SG11201900907YA (en) | 2016-08-03 | 2019-02-27 | Harvard College | Adenosine nucleobase editors and uses thereof |
WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
CN110214180A (zh) | 2016-10-14 | 2019-09-06 | 哈佛大学的校长及成员们 | 核碱基编辑器的aav递送 |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
US20190382751A1 (en) * | 2016-12-28 | 2019-12-19 | Ionis Pharmaceuticals, Inc. | Modified crispr rna and uses thereof |
EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
EP3592777A1 (en) | 2017-03-10 | 2020-01-15 | President and Fellows of Harvard College | Cytosine to guanine base editor |
CN110914426A (zh) | 2017-03-23 | 2020-03-24 | 哈佛大学的校长及成员们 | 包含核酸可编程dna结合蛋白的核碱基编辑器 |
WO2018201086A1 (en) | 2017-04-28 | 2018-11-01 | Editas Medicine, Inc. | Methods and systems for analyzing guide rna molecules |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
CN110997908A (zh) | 2017-06-09 | 2020-04-10 | 爱迪塔斯医药公司 | 工程化的cas9核酸酶 |
EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11709156B2 (en) | 2017-09-18 | 2023-07-25 | Waters Technologies Corporation | Use of vapor deposition coated flow paths for improved analytical analysis |
US11709155B2 (en) | 2017-09-18 | 2023-07-25 | Waters Technologies Corporation | Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes |
JP2021500036A (ja) | 2017-10-16 | 2021-01-07 | ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. | アデノシン塩基編集因子の使用 |
WO2020033774A1 (en) * | 2018-08-08 | 2020-02-13 | Integrated Dna Technologies, Inc. | Novel mutations that enhance the dna cleavage activity of acidaminococcus sp. cpf1 |
JP7216877B2 (ja) * | 2018-10-29 | 2023-02-02 | 中国▲農▼▲業▼大学 | 新規なCRISPR/Cas12f酵素およびシステム |
CN109652861A (zh) * | 2018-12-22 | 2019-04-19 | 阅尔基因技术(苏州)有限公司 | 一种生化试剂盒及其应用方法 |
US20200216825A1 (en) * | 2019-01-08 | 2020-07-09 | Integrated Dna Technologies, Inc. | CAS12a MUTANT GENES AND POLYPEPTIDES ENCODED BY SAME |
BR112021018607A2 (pt) | 2019-03-19 | 2021-11-23 | Massachusetts Inst Technology | Métodos e composições para editar sequências de nucleotídeos |
KR102551876B1 (ko) * | 2019-12-18 | 2023-07-05 | 한국생명공학연구원 | Cpf1 및 키메릭 DNA-RNA 가이드를 포함하는 유전체 교정 또는 발현 억제용 조성물 |
CN110904239B (zh) * | 2019-12-25 | 2020-11-10 | 武汉博杰生物医学科技有限公司 | 肺癌相关分子标志物基因突变的检测试剂盒与检测方法 |
CN110894530B (zh) * | 2019-12-25 | 2020-12-08 | 武汉博杰生物医学科技有限公司 | 结肠癌相关分子标志物基因突变的检测试剂盒与检测方法 |
US11918936B2 (en) | 2020-01-17 | 2024-03-05 | Waters Technologies Corporation | Performance and dynamic range for oligonucleotide bioanalysis through reduction of non specific binding |
US12012433B1 (en) | 2020-02-27 | 2024-06-18 | Integrated Dna Technologies Inc. | Expression and purification of Cas enzymes |
WO2021216674A1 (en) * | 2020-04-24 | 2021-10-28 | University Of Massachusetts | Improved cas 12a/nls mediated therapeutic gene editing platforms |
JP2023524066A (ja) | 2020-05-01 | 2023-06-08 | インテグレーティッド ディーエヌエイ テクノロジーズ インコーポレーティッド | 非カノニカルttttプロトスペーサー隣接モチーフにて増強された切断活性を備えるラクノスピラセsp.のcas12a変異体 |
CN116096873A (zh) | 2020-05-08 | 2023-05-09 | 布罗德研究所股份有限公司 | 同时编辑靶标双链核苷酸序列的两条链的方法和组合物 |
CN114657177A (zh) * | 2020-12-24 | 2022-06-24 | 中国科学院微生物研究所 | 一种利用I型CRISPR-Cas系统同时实现基因编辑和转录调控的方法 |
US20240200059A1 (en) | 2021-04-09 | 2024-06-20 | Vor Biopharma Inc. | Photocleavable guide rnas and methods of use thereof |
CN113355362B (zh) * | 2021-06-16 | 2022-06-07 | 北京大学 | 化学修饰CRISPR/Cpf1复合物的用途 |
WO2023283585A2 (en) | 2021-07-06 | 2023-01-12 | Vor Biopharma Inc. | Inhibitor oligonucleotides and methods of use thereof |
CA3228272A1 (en) | 2021-08-02 | 2023-02-09 | Vor Biopharma Inc. | Compositions and methods for gene modification |
WO2023049926A2 (en) | 2021-09-27 | 2023-03-30 | Vor Biopharma Inc. | Fusion polypeptides for genetic editing and methods of use thereof |
EP4299733A1 (en) * | 2022-06-30 | 2024-01-03 | Inari Agriculture Technology, Inc. | Compositions, systems, and methods for genome editing |
WO2024073751A1 (en) | 2022-09-29 | 2024-04-04 | Vor Biopharma Inc. | Methods and compositions for gene modification and enrichment |
CN116286737B (zh) * | 2023-01-02 | 2023-09-22 | 华中农业大学 | 无pam限制的核酸内切酶及其介导的基因编辑系统 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2061416T3 (es) | 1990-10-12 | 1997-03-01 | Max Planck Gesellschaft | Ribozimas modificadas. |
US6248878B1 (en) | 1996-12-24 | 2001-06-19 | Ribozyme Pharmaceuticals, Inc. | Nucleoside analogs |
US9895451B2 (en) | 2011-12-02 | 2018-02-20 | Yale University | Formulations for targeted release of agents to low pH tissue environments or cellular compartments and methods of use thereof |
EP3372679A1 (en) | 2012-10-23 | 2018-09-12 | Toolgen Incorporated | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof |
CN113528577A (zh) | 2012-12-12 | 2021-10-22 | 布罗德研究所有限公司 | 用于序列操纵的系统、方法和优化的指导组合物的工程化 |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
WO2014124226A1 (en) | 2013-02-07 | 2014-08-14 | The Rockefeller University | Sequence specific antimicrobials |
EP3988667A1 (en) | 2013-03-15 | 2022-04-27 | The General Hospital Corporation | Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing |
US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
US20150067922A1 (en) | 2013-05-30 | 2015-03-05 | The Penn State Research Foundation | Gene targeting and genetic modification of plants via rna-guided genome editing |
MX361154B (es) | 2013-08-22 | 2018-11-28 | Pioneer Hi Bred Int | Modificación del genoma usando sistemas guía de polinucleótido/cas endonucleasa y métodos de uso. |
US10435685B2 (en) | 2014-08-19 | 2019-10-08 | Pacific Biosciences Of California, Inc. | Compositions and methods for enrichment of nucleic acids |
JP6190995B2 (ja) | 2014-11-17 | 2017-09-06 | 国立大学法人 東京医科歯科大学 | 簡便で高効率の遺伝子改変非ヒト哺乳動物の作製方法 |
US10900034B2 (en) | 2014-12-03 | 2021-01-26 | Agilent Technologies, Inc. | Guide RNA with chemical modifications |
CN112877327A (zh) | 2014-12-18 | 2021-06-01 | 综合基因技术公司 | 基于crispr的组合物和使用方法 |
WO2016115179A1 (en) * | 2015-01-12 | 2016-07-21 | Massachusetts Institute Of Technology | Gene editing through microfluidic delivery |
FI3250691T3 (fi) | 2015-01-28 | 2023-08-24 | Caribou Biosciences Inc | Crispr hybridi dna/rna polynukleotidit ja käyttömenetelmät |
JP2018513681A (ja) * | 2015-03-31 | 2018-05-31 | エクセリゲン サイエンティフィック, インコーポレイテッドExeligen Scientific, Inc. | 細胞または生物のゲノムへのDNA配列の標的化組み込みのためのCas9レトロウイルスインテグラーゼおよびCas9レコンビナーゼ系 |
EP3280803B1 (en) | 2015-04-06 | 2021-05-26 | The Board of Trustees of the Leland Stanford Junior University | Chemically modified guide rnas for crispr/cas-mediated gene regulation |
US20160362667A1 (en) | 2015-06-10 | 2016-12-15 | Caribou Biosciences, Inc. | CRISPR-Cas Compositions and Methods |
US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
JP6799058B2 (ja) | 2015-09-21 | 2020-12-09 | アークトゥラス・セラピューティクス・インコーポレイテッドArcturus Therapeutics,Inc. | アレル選択的な遺伝子編集およびその使用 |
US20170246260A1 (en) | 2016-02-25 | 2017-08-31 | Agenovir Corporation | Modified antiviral nuclease |
WO2017184786A1 (en) * | 2016-04-19 | 2017-10-26 | The Broad Institute Inc. | Cpf1 complexes with reduced indel activity |
AU2017257274B2 (en) | 2016-04-19 | 2023-07-13 | Massachusetts Institute Of Technology | Novel CRISPR enzymes and systems |
KR102670601B1 (ko) * | 2016-04-19 | 2024-05-29 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신규한 crispr 효소 및 시스템 |
CN109415729B (zh) | 2016-04-21 | 2022-12-09 | 生命技术公司 | 具有降低毒性的基因编辑试剂 |
CN106244591A (zh) * | 2016-08-23 | 2016-12-21 | 苏州吉玛基因股份有限公司 | 修饰crRNA在CRISPR/Cpf1基因编辑系统中的应用 |
-
2017
- 2017-11-22 CN CN201780072070.XA patent/CN110402287A/zh active Pending
- 2017-11-22 AU AU2017364084A patent/AU2017364084A1/en active Pending
- 2017-11-22 EP EP23199206.6A patent/EP4321617A3/en active Pending
- 2017-11-22 CA CA3044101A patent/CA3044101A1/en active Pending
- 2017-11-22 JP JP2019527441A patent/JP2019535287A/ja active Pending
- 2017-11-22 KR KR1020197018073A patent/KR20190082318A/ko not_active Application Discontinuation
- 2017-11-22 US US15/821,736 patent/US11136567B2/en active Active
- 2017-11-22 WO PCT/US2017/063161 patent/WO2018098383A1/en unknown
- 2017-11-22 EP EP17873549.4A patent/EP3545085A4/en not_active Ceased
-
2021
- 2021-09-08 US US17/469,578 patent/US20220002693A1/en active Pending
-
2022
- 2022-12-02 JP JP2022193427A patent/JP2023022254A/ja active Pending
Non-Patent Citations (3)
Title |
---|
ANGEW. CHEM. INT. ED., vol. 55, JPN6021034861, 2016, pages 3548 - 3550, ISSN: 0004839860 * |
CELL, vol. 163, JPN6021034863, 2015, pages 759 - 771, ISSN: 0004839858 * |
MOLECULAR PLANT, vol. 10, JPN6021034862, 16 March 2017 (2017-03-16), pages 1011 - 1013, ISSN: 0004839859 * |
Also Published As
Publication number | Publication date |
---|---|
EP4321617A2 (en) | 2024-02-14 |
AU2017364084A1 (en) | 2019-05-16 |
CA3044101A1 (en) | 2018-05-31 |
US11136567B2 (en) | 2021-10-05 |
US20220002693A1 (en) | 2022-01-06 |
CN110402287A (zh) | 2019-11-01 |
EP3545085A4 (en) | 2020-10-28 |
EP3545085A1 (en) | 2019-10-02 |
JP2023022254A (ja) | 2023-02-14 |
KR20190082318A (ko) | 2019-07-09 |
EP4321617A3 (en) | 2024-04-24 |
WO2018098383A1 (en) | 2018-05-31 |
US20180187176A1 (en) | 2018-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019535287A (ja) | Crispr/cpf1システム及び方法 | |
US11427818B2 (en) | S. pyogenes CAS9 mutant genes and polypeptides encoded by same | |
US11913014B2 (en) | S. pyogenes Cas9 mutant genes and polypeptides encoded by same | |
JP6649468B2 (ja) | 操作されたcrispr−cas9組成物及び使用方法 | |
KR102093570B1 (ko) | 조작된 핵산 표적화 핵산 | |
CN111328343A (zh) | Rna靶向方法和组合物 | |
US20160186214A1 (en) | Modified cascade ribonucleoproteins and uses thereof | |
US20210403924A1 (en) | Method for selecting cells based on CRISPR/Cas-mediated integration of a detectable tag to a target protein | |
WO2022013133A1 (en) | Methods for modulating cas-effector activity | |
JP7506405B2 (ja) | 真核生物の遺伝子編集のためのレンチウイルスベースのベクターならびに関連システムおよび方法 | |
EP4097224A1 (en) | Tools and methods for mycoplasma engineering | |
Wedel | Transkription in Trypanosoma brucei |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200824 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210907 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211201 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220307 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220802 |